[Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia]

by Selleckchem | Oct 21 2023

Objective: To explore the efficacy of tyrosine kinase inhibitor (TKI) combined with decitabine, homoharringtonine, and interferon regimen as maintenance therapy for blast phase chronic myeloid leukemia (CML-BP).

Methods: The clinical data of CML-BP patients who received the first major hematological response after induction therapy at The Affiliated Cancer Hospital of Zhengzhou University from June 2015 to December 2021 were analyzed retrospectively. The event-free survival, duration of remission, and overall survival of patients in TKI combined with decitabine, homoharringtonine, interferon group(n=18) and TKI combined with conventional chemotherapy group(n=10) were compared by log-rank test.

Results: A total of 28 patients were included, with a median age of 46 (24-58) years old. Kaplan-Meier survival analysis showed that patients in TKI combined with decitabine, homoharringtonine, interferon group had longer event-free survival (7.4 vs 4.3 months, P=0.043, HR＝0.44, 95% CI: 0.17-1.14), duration of overall remission (16.1 vs 6.6 months, P=0.005, HR＝0.32, 95% CI: 0.11-0.89), overall survival (34.3 vs 13.5 months, P=0.006, HR＝0.29, 95% CI: 0.10-0.82) compared with patients in TKI combined with conventional chemotherapy group.

Conclusion: The TKI combined with decitabine, homoharringtonine and interferon regimen can significantly prolong the survival of CML-BP patients who obtained the major hematological response compared with TKI combined with conventional chemotherapy regimen.

Comments:

Title: Efficacy of Tyrosine Kinase Inhibitor (TKI) Combined with Decitabine, Homoharringtonine, and Interferon as Maintenance Therapy for Blast Phase Chronic Myeloid Leukemia (CML-BP)

Objective: The objective of this study was to explore the efficacy of a regimen combining tyrosine kinase inhibitor (TKI) with decitabine, homoharringtonine, and interferon as maintenance therapy for patients with blast phase chronic myeloid leukemia (CML-BP).

Methods: The researchers conducted a retrospective analysis of clinical data from CML-BP patients who received induction therapy and achieved the first major hematological response at The Affiliated Cancer Hospital of Zhengzhou University between June 2015 and December 2021. Two groups were compared: the TKI combined with decitabine, homoharringtonine, and interferon group (n=18) and the TKI combined with conventional chemotherapy group (n=10). The analysis compared the event-free survival, duration of remission, and overall survival between the two groups using the log-rank test.

Results: A total of 28 patients with CML-BP were included in the study, with a median age of 46 years (range: 24-58 years). The Kaplan-Meier survival analysis demonstrated the following findings:

1. Event-Free Survival: Patients in the TKI combined with decitabine, homoharringtonine, and interferon group had a significantly longer event-free survival compared to those in the TKI combined with conventional chemotherapy group (7.4 months vs. 4.3 months, P=0.043, HR=0.44, 95% CI: 0.17-1.14).

2. Duration of Remission: Patients in the TKI combined with decitabine, homoharringtonine, and interferon group had a significantly longer duration of overall remission compared to those in the TKI combined with conventional chemotherapy group (16.1 months vs. 6.6 months, P=0.005, HR=0.32, 95% CI: 0.11-0.89).

3. Overall Survival: Patients in the TKI combined with decitabine, homoharringtonine, and interferon group had a significantly longer overall survival compared to those in the TKI combined with conventional chemotherapy group (34.3 months vs. 13.5 months, P=0.006, HR=0.29, 95% CI: 0.10-0.82).

Conclusion: The study suggests that the combination of TKI with decitabine, homoharringtonine, and interferon as a maintenance therapy regimen significantly prolongs the event-free survival, duration of remission, and overall survival of CML-BP patients who have achieved a major hematological response compared to a regimen combining TKI with conventional chemotherapy. These findings indicate the potential efficacy of the TKI combined with decitabine, homoharringtonine, and interferon regimen in managing CML-BP. However, further prospective studies are needed to validate these results and assess the safety and long-term outcomes of this therapeutic approach.